Abstract:Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths world-wide. EBV is also the primary cause of infectious mononucleosis, and up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis. In addition, EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis. An EBV prophylactic vaccine that induces neutralizing antibodies holds great promise for prevention of EBV associated diseases. EBV envelope proteins including gH/gL, gB and gp350 play key roles in EBV entry and infection of target cells, and neutralizing antibodies elicited by each of these proteins have shown to prevent EBV infection of target cells and markedly decrease EBV titers in the peripheral blood of humanized mice challenged with lethal dose EBV. Recent studies demonstrated that immunization with the combination of gH/gL, gB and/or gp350 induced markedly increased synergistic EBV neutralizing activity compared to immunization with individual proteins. As previous clinical trials focused on gp350 alone were partially successful, the inclusion of gH/gL and gB in a vaccine formulation with gp350 represents a promising approach of EBV prophylactic vaccine development. Therapeutic EBV vaccines have also been tested clinically with encouraging results. Immunization with various vaccine platforms expressing the EBV latent proteins EBNA1, LMP1, and/or LMP2 promoted specific CD4+ and CD8+ cytotoxic responses with anti-tumor activity. The addition of EBV envelope proteins gH/gL, gB and gp350 has the potential to increase the efficacy of a therapeutic EBV vaccine. The immune system plays a critical role in the control of tumors, and immune cell therapy has emerged as a promising treatment of cancers. Adoptive T-cell therapy has been successfully used in the prevention and treatment of post-transplant lymphoproliferative disorder. Chimeric antigen receptor T cell therapy and T cell receptor engineered T cell therapy targeting EBV latent proteins LMP1, LMP2 and/or EBNA1 have been in development, with the goal to increase the specificity and efficacy of treatment of EBV associated cancers.

Therapies based on targeting EBV lytic replication for EBV-associated malignancies.

The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies

Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation

Treatment Advances in EBV Related Lymphoproliferative Diseases

Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

Treatment of Epstein-Barr Virus infection in immunocompromised patients

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma

The Novel Immune Landscape of Immune-Checkpoint Blockade in EBV-associated Malignancies.

Targeting latent viral infection in EBV-associated lymphomas

Epstein‒Barr virus-associated cellular immunotherapy

Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis.

The lytic phase of Epstein-Barr virus plays an important role in tumorigenesis

New insights into Epstein-Barr virus-associated tumors: Exosomes

Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma

Activation of Lytic Epstein-Barr Virus (EBV) Infection by Radiation and Sodium Butyrate in Vitro and in Vivo: a Potential Method for Treating EBV-positive Malignancies.

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment

Immune Modulation by Epstein–Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis

Regulatory T cells and EBV associated malignancies

Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers